Our platform represents a fundamentally new approach to immunotherapy. Our therapies have the potential to offer a cure for patients with the most difficult to treat hematologic conditions.
Recent Posts
- Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies
- Cimeio Therapeutics Therapy Platform Featured in Forbes Article
- Selective haematological cancer eradication with preserved haematopoiesis
- Cimeio Therapeutics Announces Publication in Nature Demonstrating That CD45 ADC and Shielded HSCs Represent a Potentially Universal Therapy for Blood Cancers
- Molecular shielding of CD52 retains expression, anti-phagocytic ‘don’t eat me’ function and protects from Alemtuzumab-mediated depletion
Recent Comments
No comments to show.